^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

CD30 inhibitor

Phase 2
Affimed GmbH
Recruiting
Last update posted :
05/27/2024
Initiation :
10/10/2023
Primary completion :
04/30/2026
Completion :
11/30/2027
ALK • TNFRSF8
|
ALK positive • TNFRSF8 positive • ALK negative
|
cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)
Phase 1
UNC Lineberger Comprehensive Cancer Center
Recruiting
Last update posted :
04/23/2024
Initiation :
09/01/2019
Primary completion :
04/01/2025
Completion :
07/07/2037
TNFRSF8 • CCR4
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
04/18/2024
Initiation :
07/18/2020
Primary completion :
04/15/2025
Completion :
04/15/2025
TNFRSF8
|
TNFRSF8 positive
|
cyclophosphamide • fludarabine IV • acimtamig (AFM13) • cyclophosphamide intravenous
Phase 1/2
Medical College of Wisconsin
Not yet recruiting
Last update posted :
03/22/2024
Initiation :
12/01/2024
Primary completion :
01/01/2027
Completion :
01/01/2027
TNFRSF8
|
TNFRSF8 expression
|
CD30 biAb-AATC
Phase 2
Affimed GmbH
Completed
Last update posted :
02/02/2024
Initiation :
11/13/2019
Primary completion :
05/11/2022
Completion :
01/11/2024
TNFRSF8
|
TNFRSF8 positive
|
acimtamig (AFM13)
Phase 1/2
Ahmed Sawas
Completed
Last update posted :
07/20/2023
Initiation :
07/17/2017
Primary completion :
04/01/2020
Completion :
04/01/2020
TNFRSF8
|
TNFRSF8 positive
|
acimtamig (AFM13)
Phase 2
University of Cologne
Completed
Last update posted :
11/13/2020
Initiation :
05/01/2015
Primary completion :
11/01/2019
Completion :
07/01/2020
PD-L1
|
acimtamig (AFM13)
Phase 1b
Affimed GmbH
Completed
Last update posted :
05/16/2019
Initiation :
05/01/2016
Primary completion :
01/01/2019
Completion :
03/01/2019
TNFRSF8
|
Keytruda (pembrolizumab) • acimtamig (AFM13)